CLEC2抗体;CLEC2 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CLEC2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder Cancer tissues using CLEC2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using CLEC2 mouse mAb with DAB staining.    

  
  

CLEC2 (C-type lectin-like receptor 2) is a transmembrane protein belonging to the C-type lectin family, primarily expressed on platelets, dendritic cells, and myeloid cells. It functions as a signaling receptor through its cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM). CLEC2 interacts with podoplanin (PDPN), a glycoprotein expressed on lymphatic endothelial cells, certain immune cells, and tumor cells. This interaction is critical in platelet activation, thrombosis, and maintenance of vascular integrity. Notably, CLEC2 binding to PDPN on lymphatic endothelial cells prevents blood-lymph mixing during development by stabilizing connections between lymphatic and blood vessels.

In pathological contexts, CLEC2-PDPN signaling contributes to cancer metastasis by promoting platelet aggregation around tumor cells, facilitating their survival in circulation. CLEC2 also regulates immune responses, influencing dendritic cell maturation and T-cell interactions. Anti-CLEC2 antibodies, often used as research tools, block CLEC2-mediated signaling and have revealed its roles in thrombosis, inflammation, and tumor progression. Therapeutic targeting of CLEC2 is explored for antithrombotic therapies or cancer treatment, though challenges remain in specificity and off-target effects. Dysregulated CLEC2 expression or signaling is implicated in autoimmune disorders and thromboinflammatory diseases, underscoring its biological and clinical relevance.